Cargando…
Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561601/ https://www.ncbi.nlm.nih.gov/pubmed/37818356 http://dx.doi.org/10.3389/fimmu.2023.1282155 |
| _version_ | 1785117958328025088 |
|---|---|
| author | Tang, Guo-Qing Tang, Yalan Dhamnaskar, Ketki Hoarty, Michelle D. Vyasamneni, Rohit Vadysirisack, Douangsone D. Ma, Zhong Zhu, Nanqun Wang, Jian-Guo Bu, Charlie Cong, Bestine Palmer, Elizabeth Duda, Petra W. Sayegh, Camil Ricardo, Alonso |
| author_facet | Tang, Guo-Qing Tang, Yalan Dhamnaskar, Ketki Hoarty, Michelle D. Vyasamneni, Rohit Vadysirisack, Douangsone D. Ma, Zhong Zhu, Nanqun Wang, Jian-Guo Bu, Charlie Cong, Bestine Palmer, Elizabeth Duda, Petra W. Sayegh, Camil Ricardo, Alonso |
| author_sort | Tang, Guo-Qing |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10561601 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105616012023-10-10 Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation Tang, Guo-Qing Tang, Yalan Dhamnaskar, Ketki Hoarty, Michelle D. Vyasamneni, Rohit Vadysirisack, Douangsone D. Ma, Zhong Zhu, Nanqun Wang, Jian-Guo Bu, Charlie Cong, Bestine Palmer, Elizabeth Duda, Petra W. Sayegh, Camil Ricardo, Alonso Front Immunol Immunology Frontiers Media S.A. 2023-09-25 /pmc/articles/PMC10561601/ /pubmed/37818356 http://dx.doi.org/10.3389/fimmu.2023.1282155 Text en Copyright © 2023 Tang, Tang, Dhamnaskar, Hoarty, Vyasamneni, Vadysirisack, Ma, Zhu, Wang, Bu, Cong, Palmer, Duda, Sayegh and Ricardo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Immunology Tang, Guo-Qing Tang, Yalan Dhamnaskar, Ketki Hoarty, Michelle D. Vyasamneni, Rohit Vadysirisack, Douangsone D. Ma, Zhong Zhu, Nanqun Wang, Jian-Guo Bu, Charlie Cong, Bestine Palmer, Elizabeth Duda, Petra W. Sayegh, Camil Ricardo, Alonso Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation |
| title | Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation |
| title_full | Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation |
| title_fullStr | Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation |
| title_full_unstemmed | Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation |
| title_short | Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation |
| title_sort | corrigendum: zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation |
| topic | Immunology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561601/ https://www.ncbi.nlm.nih.gov/pubmed/37818356 http://dx.doi.org/10.3389/fimmu.2023.1282155 |
| work_keys_str_mv | AT tangguoqing corrigendumzilucoplanamacrocyclicpeptideinhibitorofhumancomplementcomponent5usesadualmodeofactiontopreventterminalcomplementpathwayactivation AT tangyalan corrigendumzilucoplanamacrocyclicpeptideinhibitorofhumancomplementcomponent5usesadualmodeofactiontopreventterminalcomplementpathwayactivation AT dhamnaskarketki corrigendumzilucoplanamacrocyclicpeptideinhibitorofhumancomplementcomponent5usesadualmodeofactiontopreventterminalcomplementpathwayactivation AT hoartymichelled corrigendumzilucoplanamacrocyclicpeptideinhibitorofhumancomplementcomponent5usesadualmodeofactiontopreventterminalcomplementpathwayactivation AT vyasamnenirohit corrigendumzilucoplanamacrocyclicpeptideinhibitorofhumancomplementcomponent5usesadualmodeofactiontopreventterminalcomplementpathwayactivation AT vadysirisackdouangsoned corrigendumzilucoplanamacrocyclicpeptideinhibitorofhumancomplementcomponent5usesadualmodeofactiontopreventterminalcomplementpathwayactivation AT mazhong corrigendumzilucoplanamacrocyclicpeptideinhibitorofhumancomplementcomponent5usesadualmodeofactiontopreventterminalcomplementpathwayactivation AT zhunanqun corrigendumzilucoplanamacrocyclicpeptideinhibitorofhumancomplementcomponent5usesadualmodeofactiontopreventterminalcomplementpathwayactivation AT wangjianguo corrigendumzilucoplanamacrocyclicpeptideinhibitorofhumancomplementcomponent5usesadualmodeofactiontopreventterminalcomplementpathwayactivation AT bucharlie corrigendumzilucoplanamacrocyclicpeptideinhibitorofhumancomplementcomponent5usesadualmodeofactiontopreventterminalcomplementpathwayactivation AT congbestine corrigendumzilucoplanamacrocyclicpeptideinhibitorofhumancomplementcomponent5usesadualmodeofactiontopreventterminalcomplementpathwayactivation AT palmerelizabeth corrigendumzilucoplanamacrocyclicpeptideinhibitorofhumancomplementcomponent5usesadualmodeofactiontopreventterminalcomplementpathwayactivation AT dudapetraw corrigendumzilucoplanamacrocyclicpeptideinhibitorofhumancomplementcomponent5usesadualmodeofactiontopreventterminalcomplementpathwayactivation AT sayeghcamil corrigendumzilucoplanamacrocyclicpeptideinhibitorofhumancomplementcomponent5usesadualmodeofactiontopreventterminalcomplementpathwayactivation AT ricardoalonso corrigendumzilucoplanamacrocyclicpeptideinhibitorofhumancomplementcomponent5usesadualmodeofactiontopreventterminalcomplementpathwayactivation |